Nyrada Inc (ASX: NYR) Share Price and News

Dr Dixon brings to the Board a technical and entrepreneurial background in founding, building and running technology-based companies, in recognising the potential commercial value of early-stage drug development, and in understanding the challenges involved in drug development. In 2011, Dr Dixon co-founded Cynata Inc, now a subsidiary of ASX-listed Cynata Therapeutics Ltd. He is member of Risk committee.

Mr Moore currently serves as Chairman of Trialogics, a clinical trial informatics business, Chairman of Scientific Industries (SCND-OTCQB), a producer of laboratory instruments for the life sciences industry and Chairman of Cormetech, a manufacturer of environmental catalysts. John was CEO of Acorn Energy from 2006 to 2015, during which time the CoaLogix business was acquired for US$11 million and sold for US$101 million, and the Comverge business listed in the US before its sale to Constellation Energy. In 2002 he was a Partner and CEO of Edson Moore Healthcare Ventures and acquired for US$148 million a portfolio of sixteen drug delivery investments from Elan Pharmaceuticals. He is a member of Risk Committee.

Mr Weseloh is an Executive Director of Business Development at EMD Serono, Inc, Rockland, MA, USA., where over a period of 17 years he has led more than 80 transactions for the health care division of its parent company Merck KGaA, Darmstadt, Germany. Completed deals across the drug development value chain were in the fields of Oncology, Rheumatology, Neurodegenerative diseases, and Fertility. Before joining Merck KGaA, Ruediger spent 5 years as a Biotech/Pharma Equity Analyst, at Gontard & Metallbank AG, Frankfurt, and Sal. Oppenheim, Cologne/Frankfurt, as well as 3 years as a Postdoc at the Max-Planck Institute for Experimental Medicine in Goettingen.

Mr Cox is a Co-Founder and has been a Managing Partner of Population Health Partners since April 2020. Chris is a retired Partner of Cadwalader, Wickersham & Taft LLP a position he held from January 2012. He remains a Senior Attorney of the firm. Previously the Chairman of Cadwalader's Corporate Department and a member of its Management Committee, Chris advised clients on a wide array of corporate and financial matters, including mergers and acquisitions and restructurings, spin-offs, joint ventures, IP monetization's and other complex financing transactions. From February 2016 to March 2019, Chris was seconded to The Medicines Company, a global biopharmaceutical company, where he served as Executive Vice President and Chief Corporate Development Officer and was responsible for business development and strategy.

Mr Frampton currently serves as the Chief Investment Officer of the Alaska Permanent Fund Corporation (APFC), the US$77 billion sovereign wealth fund for the State of Alaska. Marcus manages the investment team at APFC and leads all investment decisions related to APFC's investment portfolio within the guidelines established by APFC's Board of Trustees. Before joining the APFC in 2012, Marcus held positions ranging from Investment Banking Analyst & Associate at Lehman Brothers (2002-2005) to private equity investing at PCG Capital Partners (2005-2010) and acted as an executive of a private equity-backed portfolio company at LPL Financial (2010-2012). He is a member of Risk Committee.

Ms Mautner is an international business leader with experience in developing and launching new pharmaceutical products and delivering corporate strategies in highly competitive global markets. Gisela has held senior positions with Amgen, Bayer, Siemens Medical Solutions and Merck/MSD generating commercial and scientific outcomes. She is currently the Past-President of the Medical Affairs Professionals Association of Australasia (MAPA) and a Member of the Australian Institute of Company Directors and the CEO Institute. She is also a Non-executive Director of a not-for-profit organization.

-

-

-

-